Identification and Biopsy of Sentinel Lymph Node in Early-Stage Cervical Carcinoma: Diagnostic Accuracy and Clinical Utility.
lymph node biopsy
lymphatic mapping
methylene blue
sentinel
uterine cervical cancer
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
accepted:
05
04
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
Background Due to the subsequent complications of pelvic lymphadenectomy in patients with early-stage cervical cancer, the sentinel lymph node (SLN) technique has been increasingly employed. This study aimed to investigate the detectability of SLN using methylene blue and explore the diagnostic accuracy of SLN biopsy. Methodology A study was conducted from September 2015 to August 2018 and included 90 women with cervical cancer, FIGO (International Federation of Gynecology and Obstetrics-2009) stage IA1-IIA1. Methylene blue was injected intracervically. Any detected dyed nodes were sent for frozen section biopsy, followed by bilateral pelvic lymphadenectomy. The predictive ability of SLN was evaluated in statistical terms after comparison of intraoperative biopsy and final histopathology. Results The sensitivity, specificity, false-negative rate, positive predictive value, and negative predictive value (NPV) were 55.6%, 95.1%, 4.9%, 55.6%, and 95.1%, respectively. The SLN performance in patients with tumor size ≤2.2 cm, negative lymphovascular space involvement, and depth of stromal invasion ≤5 mm was superior (sensitivity 100%, specificity 93.5%, NPV 100%). Conclusions The SLN technique with blue dye alone is a feasible and adequate alternative to systematic lymphadenectomy in early-stage cervical cancer in selected patients, given that a strict algorithm is applied.
Identifiants
pubmed: 35530888
doi: 10.7759/cureus.23838
pmc: PMC9070105
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e23838Informations de copyright
Copyright © 2022, Koutroumpa et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Semin Nucl Med. 2019 Nov;49(6):521-533
pubmed: 31630736
Int J Gynecol Cancer. 2015 Oct;25(8):1513-8
pubmed: 26397069
Semin Ultrasound CT MR. 2019 Aug;40(4):280-286
pubmed: 31375168
J Minim Invasive Gynecol. 2014 Jul-Aug;21(4):540-5
pubmed: 24407177
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36
pubmed: 30306584
Gynecol Surg. 2017;14(1):23
pubmed: 29213225
Curr Opin Obstet Gynecol. 2015 Feb;27(1):66-72
pubmed: 25502426
Rep Pract Oncol Radiother. 2018 Nov-Dec;23(6):495-502
pubmed: 30534012
Gynecol Oncol. 2017 Apr;145(1):96-101
pubmed: 28188015
Eur J Obstet Gynecol Reprod Biol. 2019 Oct;241:71-76
pubmed: 31450214
Ann Surg Oncol. 2016 Jul;23(7):2183-91
pubmed: 26714944
Arch Gynecol Obstet. 2011 Dec;284(6):1551-6
pubmed: 21465249
Int J Gynecol Cancer. 2018 Sep;28(7):1432-1437
pubmed: 30036220
Arch Gynecol Obstet. 2017 Sep;296(3):565-570
pubmed: 28744616
Med Oncol. 2015 Jan;32(1):385
pubmed: 25429838
Ann Surg Oncol. 2016 Oct;23(11):3749-3756
pubmed: 27160526
Eur J Obstet Gynecol Reprod Biol. 2016 Nov;206:213-219
pubmed: 27750179
Arch Gynecol Obstet. 2019 May;299(5):1373-1384
pubmed: 30762108
Gynecol Oncol. 2011 Nov;123(2):230-5
pubmed: 21893335
World J Surg Oncol. 2018 Mar 9;16(1):52
pubmed: 29523141
Int J Gynecol Cancer. 2020 Mar;30(3):387-393
pubmed: 31953349
Lancet Oncol. 2018 Oct;19(10):1394-1403
pubmed: 30143441
Histopathology. 2020 Jan;76(1):139-150
pubmed: 31846525